Story
MarineMax Soars on Buyout Report; Tenax and Sionna Plummet on Failed Drug Trials

Shares of boat retailer MarineMax Inc. surged in premarket trading Monday following a report of a potential buyout, while biotechnology firms Tenax Therapeutics and Sionna Therapeutics saw their stocks plummet after both announced failed clinical trials.
MarineMax Jumps on Acquisition News
MarineMax (HZO) shares jumped more than 34% in premarket activity after Reuters reported that Safe Harbor Marinas, which is owned by Blackstone, is nearing a deal to acquire the company. The potential transaction is valued at approximately $1.5 billion, including debt, according to the report.
The reported offer of $53 per share in cash represents a substantial premium to MarineMax's closing price of $35.68 on Friday. The deal would value the boat retailer's equity at roughly $1.17 billion.
Biotech Trial Failures Trigger Sell-Offs
In the biotechnology sector, two companies experienced massive sell-offs after reporting disappointing clinical data.
Tenax Therapeutics
AdTenax Therapeutics (TENX) stock plunged 84.2% after the company announced its Phase 3 LEVEL trial for TNX-103, an oral formulation of levosimendan, failed to meet its primary endpoint. The study did not demonstrate a statistically significant improvement in a six-minute walk distance test for patients with a specific type of heart failure, reporting a p-value of 0.63.
Sionna Therapeutics
Sionna Therapeutics (SION) shares collapsed, falling 92.1% after its Phase 2a trial of SION-719 also missed its primary goal. The trial failed to show a meaningful improvement in CFTR function for cystic fibrosis patients, with results that were statistically indistinguishable from a placebo (p-value of 0.7). Sionna stated it will not advance the drug as an add-on to standard treatments based on these results.
Other Notable Premarket Movers
Several other companies saw significant price movement before the opening bell:
- AAON (AAON): Shares surged more than 10.6% after the heating and cooling equipment manufacturer released second-quarter results that appeared to surpass analyst expectations.
- Dole (DOLE): The stock fell 4.2% after the fresh produce company reported second-quarter earnings and revenue that missed Wall Street consensus estimates.
- AirSculpt Technologies (AIRS): Shares dropped 18.4% after the company reported a 3% year-over-year decline in second-quarter revenue and a wider net loss.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.